Complement-Based Drug Development Summit leaderboard
  • Wednesday, September 30, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

17th World ADC San Diego Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 13

Author

Pharma Journalist 9091 posts 0 comments

Ember and Alfresa Partner to Strengthen Japan’s Pharma Cold Chain

Jul 29, 2026
Ember LifeSciences has entered into a capital and business alliance with Alfresa Corporation to strengthen pharmaceutical cold chain logistics in Japan and expand access to advanced…
Read More...

Shionogi Launches XOCOVA for COVID-19 Prevention in US

Jul 29, 2026
Shionogi has announced the US availability of XOCOVA (ensitrelvir), an oral antiviral approved by the US Food and Drug Administration (FDA) for post-exposure prophylaxis (PEP) of…
Read More...

From Innovation to Acquisition: CrossBridge Bio’s ADC Journey

Jul 29, 2026
As investment, innovation, and dealmaking continue to reshape the antibody-drug conjugate (ADC) landscape, Michael Torres, Chief Executive Officer of CrossBridge Bio, has shared his…
Read More...

COPD Foundations Joins the COPD Drug Development Summit

Jul 29, 2026
Are We Asking the Right Questions in COPD Drug Development? As the industry looks beyond traditional measures such as lung function and exacerbations, a new question is emerging: What…
Read More...

argenx to Acquire Forte Biosciences in $2.2 Billion Deal

Jul 29, 2026
argenx has agreed to acquire Forte Biosciences for approximately $2.2 billion in cash, strengthening its immunology pipeline with a promising experimental therapy for autoimmune…
Read More...

BioMarin, n-Lorem Join Forces on ReNU Syndrome Therapy

Jul 29, 2026
BioMarin Pharmaceutical and the n-Lorem Foundation have entered a strategic collaboration to develop what could become the first disease-modifying treatment for ReNU syndrome, a rare…
Read More...

Pfizer, Eisai Partner to Co-Promote Nurtec in Japan

Jul 29, 2026
Pfizer Japan Inc. and Eisai Co., Ltd. have announced a new collaboration to co-promote the migraine treatment Nurtec OD Tablet 75mg (rimegepant sulfate hydrate) across Japan beginning…
Read More...

Biointron Launches RushData for AI-Powered Antibody Discover

Jul 27, 2026
Biointron Biological USA Inc. has introduced RushData, a new integrated service platform designed to accelerate antibody discovery by providing rapid experimental validation for…
Read More...

FDA Approves LYTENAVA for Wet Age-Related Macular Degeneration

Jul 27, 2026
Outlook Therapeutics has secured U.S. Food and Drug Administration (FDA) approval for LYTENAVA™ (bevacizumab-vikg), making it the first and only FDA-approved ophthalmic formulation of…
Read More...

Bora to Manufacture GERD Drug for U.S. Phase 3 Trial

Jul 24, 2026
Bora Pharmaceuticals and South Korea-based Onconic Therapeutics have entered into a manufacturing agreement to support the U.S. clinical development of JAQBO, an investigational…
Read More...
Prev Next
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Biomarker Operations & Biospecimen Management
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
10th IPF Summit
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Model-Informed Drug Development Summit 2026
IMPACCT Real-World Evidence Summit
Raw Materials for Cell & Gene Therapy Summit
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
17th World ADC San Diego
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Semaglutide 2 mg Linked to Lower Cardiovascular Risk in Diabetes
  • Novo Nordisk Licenses HRS-1596 for Weekly Oral GLP-1 Therapy
  • AbbVie’s Juvmo Wins FDA Approval for Parkinson’s Disease
  • Tolerance Bio Licenses TLB-33 to Expand Thymic Health Pipeline
  • Direct RNA Binding Emerges as a Powerful Approach for Functional Disease Modulation

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

FDA, Health Canada & Leading Biopharma Organizations…

Industry Leaders Convene in Boston as Registration Remains…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.